Essential Role for Endocytosis in the Growth Factor-stimulated Activation of ERK1/2 in Endothelial Cells

VEGF signaling inside vascular endothelial cells and beyond

(2012) Anne Eichmann et al.   CURRENT OPINION IN CELL BIOLOGY

Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation

(2012) Rodney B. Luwor et al.   GROWTH FACTORS

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients

(2012) Camillo Porta et al.   ONCOLOGY

Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane

(2012) L. P. Sousa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Signal transduction by vascular endothelial growth factor receptors

(2011) Sina Koch et al.   BIOCHEMICAL JOURNAL

Fibroblast growth factors and their receptors in cancer

(2011) Jørgen Wesche et al.   BIOCHEMICAL JOURNAL

Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output

(2011) K. Ballmer-Hofer et al.   BLOOD

Role of the Clathrin Terminal Domain in Regulating Coated Pit Dynamics Revealed by Small Molecule Inhibition

(2011) Lisa von Kleist et al.   CELL

VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF

(2011) Sean M. Anderson et al.   Integrative Biology

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Endothelial α3β1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF

(2010) Rita Graça da Silva et al.   AMERICAN JOURNAL OF PATHOLOGY

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

(2010) D. J. Jonker et al.   ANNALS OF ONCOLOGY

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

VEGF Receptor 2 Endocytic Trafficking Regulates Arterial Morphogenesis

(2010) Anthony A. Lanahan et al.   DEVELOPMENTAL CELL

Mechanisms of resistance to antiangiogenesis therapy

(2010) Faisal Azam et al.   EUROPEAN JOURNAL OF CANCER

Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor

(2010) Lai Kuan Goh et al.   JOURNAL OF CELL BIOLOGY

Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis

(2010) Suphansa Sawamiphak et al.   NATURE

Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis

(2010) Yingdi Wang et al.   NATURE

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib

(2010) J C Welti et al.   ONCOGENE

VEGF receptor trafficking in angiogenesis: Figure 1

(2009) Alice Scott et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis

(2009) G. Wei et al.   BLOOD

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors

(2009) Andrew R Reynolds et al.   NATURE MEDICINE

Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way

(2009) Peter Carmeliet et al.   Nature Reviews Clinical Oncology

Endocytosis and signalling: intertwining molecular networks

(2009) Alexander Sorkin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

(2008) D. Sarker et al.   CLINICAL CANCER RESEARCH

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE